Published in Clin J Oncol Nurs on December 01, 2007
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer | NCT02549534
Persistent mobility disability after neurotoxic chemotherapy. Phys Ther (2010) 1.55
Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage (2010) 1.39
Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol (2014) 0.99
Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer (2008) 0.93
Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs (2008) 0.93
Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer (2012) 0.91
Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. Evid Based Complement Alternat Med (2013) 0.89
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol (2014) 0.88
Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evid Based Complement Alternat Med (2013) 0.88
Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research. Oncol Nurs Forum (2012) 0.88
Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer (2012) 0.86
A retrospective study of the role of an occupational therapist in the cancer nutrition rehabilitation program. Support Care Cancer (2009) 0.83
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. Cancer Manag Res (2009) 0.80
The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol (2014) 0.79
Levo-tetrahydropalmatine attenuates oxaliplatin-induced mechanical hyperalgesia in mice. Sci Rep (2014) 0.79
Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer. Cancer Nurs (2011) 0.78
Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J Adv Pract Oncol (2013) 0.77
Self-management of oxaliplatin-related peripheral neuropathy in colorectal cancer survivors. Chemother Res Pract (2013) 0.76
Whole-Body Vibration as a Modality for the Rehabilitation of Peripheral Neuropathies: Implications for Cancer Survivors Suffering from Chemotherapy-Induced Peripheral Neuropathy. Oncol Rev (2015) 0.76
Chemotherapy-Induced or Chemotherapy-Associated? Does Physical Therapy Play a Role in Prevention and/or Management of Peripheral Neurotoxicity and Neuropathy? Indian J Palliat Care (2013) 0.76
Auraptenol attenuates vincristine-induced mechanical hyperalgesia through serotonin 5-HT1A receptors. Sci Rep (2013) 0.76
Effect of Gabapentin and Pregabalin in Rat Model of Taxol Induced Neuropathic Pain. J Clin Diagn Res (2015) 0.76
Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients. Cureus (2013) 0.76
The Rehabilitation of Oncological Patients Presenting Neuropathies. Clujul Med (2014) 0.75
Acupuncture for the management of chemotherapy-induced peripheral neuropathy. J Adv Pract Oncol (2012) 0.75
Chemotherapy-induced peripheral neuropathy. Part II. Prevention. Contemp Oncol (Pozn) (2012) 0.75
The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial. Biomark Res (2016) 0.75
New data question treatment for oxaliplatin neurotoxicity. Clin J Oncol Nurs (2008) 0.75
Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis. Contemp Oncol (Pozn) (2016) 0.75
Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy. Support Care Cancer (2014) 0.75
Evaluation of the treatment of chronic chemotherapy-induced peripheral neuropathy using long-wave diathermy and interferential currents: a randomized controlled trial. Support Care Cancer (2015) 0.75
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 13.74
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 8.28
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science (2011) 6.19
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78
The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol (2001) 3.41
The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest (2006) 3.33
IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity (2002) 3.17
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol (2004) 3.15
Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med (2003) 2.71
IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol (2007) 2.71
Abrogation of Ref1 retrovirus restriction in human cells. J Virol (2002) 2.60
Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med (2003) 2.54
An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol (2007) 2.46
Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med (2002) 2.28
Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum (2007) 2.10
Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem (2007) 2.06
KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci (2003) 2.04
Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol (2003) 1.93
The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol (2008) 1.82
Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics (2003) 1.81
Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev (2008) 1.75
IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol (2003) 1.67
Continuous high-titer HIV-1 vector production. Nat Biotechnol (2003) 1.58
Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest (2004) 1.57
IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol (2003) 1.55
Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol (2010) 1.53
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol (2006) 1.52
Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol (2011) 1.51
Crystal structure of a vFlip-IKKgamma complex: insights into viral activation of the IKK signalosome. Mol Cell (2008) 1.46
HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol (2010) 1.44
IL-22 induces an acute-phase response. J Immunol (2010) 1.40
Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage. J Invasive Cardiol (2012) 1.40
Nurse case management improves blood pressure, emotional distress and diabetes complication screening. Diabetes Res Clin Pract (2005) 1.30
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med (2011) 1.27
Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol (2005) 1.26
A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol (2005) 1.23
IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest (2008) 1.17
Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med (2005) 1.17
Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J Leukoc Biol (2006) 1.11
Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett (2004) 1.11
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum (2010) 1.10
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum (2011) 1.08
IL-21 receptor is critical for the development of memory B cell responses. J Immunol (2010) 1.05
Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association. J Virol (2003) 1.05
Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J Immunol (2002) 1.04
BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol (2003) 1.04
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum (2010) 1.03
IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol (2012) 1.02
IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp Neurol (2007) 0.98
Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol (2006) 0.97
A strabismus susceptibility locus on chromosome 7p. Proc Natl Acad Sci U S A (2003) 0.97
IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22. J Mol Biol (2008) 0.97
DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine (2005) 0.97
Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat. J Virol (2010) 0.95
The β-globin locus control region in combination with the EF1α short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity. Mol Ther (2012) 0.93
Enhanced GITR/GITRL interactions augment IL-27 expression and induce IL-10-producing Tr-1 like cells. Eur J Immunol (2012) 0.92
Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J Gene Med (2007) 0.90
IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol (2005) 0.90
Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther (2005) 0.89
Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol (2005) 0.88
Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr Gene Ther (2013) 0.87
Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. J Virol (2012) 0.86
A FLIPR-based assay to assess potency and selectivity of inhibitors of the TEC family kinases Btk and Itk. Assay Drug Dev Technol (2007) 0.84
Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo. Int Immunol (2004) 0.83
Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells. J Virol (2005) 0.82
Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol Immunother (2005) 0.82
DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1. Int J Cancer (2013) 0.81
Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. Cell Immunol (2003) 0.81
Cell-surface and cytokine biomarkers in autoimmune and inflammatory diseases. Drug Discov Today (2006) 0.81
Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Support Cancer Ther (2006) 0.80
Unexpected targets and triggers of autoimmunity. J Clin Immunol (2014) 0.80
Targeting lentiviral vectors for cancer immunotherapy. Curr Cancer Ther Rev (2011) 0.80
The pathology and immunology of atopic dermatitis. Inflamm Allergy Drug Targets (2011) 0.80
The DTH effector response and IL-2 are unaffected by cyclosporine A in autoimmune B6D2F1 mice. Cell Immunol (2010) 0.78
Pilot evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther (2006) 0.78
Improving weight of evidence approaches to chemical evaluations. Risk Anal (2014) 0.77
Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs. J Immunol (2011) 0.77
Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys. Rheumatology (Oxford) (2011) 0.75
Geriatric trauma G-60 falls with hip fractures: A pilot study of acute pain management using femoral nerve fascia iliac blocks. J Trauma Acute Care Surg (2015) 0.75